Printify
Women's V-Neck Tee (Purple Ribbon)
Women's V-Neck Tee (Purple Ribbon)
Couldn't load pickup availability
Celebrate strength and resilience with the Victory V-Neck Survivor Tee, crafted specifically for pancreatic cancer survivors. This Bella+Canvas v-neck shirt combines effortless style with all-day comfort, featuring the word “Survivor” emblazoned on the back like a sports jersey—a proud statement of triumph and determination.
Made from lightweight, breathable 100% cotton fabric (with heathered options in a soft cotton-poly blend), this tee is designed to be your go-to choice, whether for casual outings or moments of celebration. Its retail fit and flattering V-neckline offer a stylish silhouette, and each shirt is manufactured under Fair Labor Association standards, ensuring garments that look good and feel good to wear.
40% of all revenue from this tee goes directly to support pancreatic cancer research, helping to fund the fight for others facing this disease. Wear your strength and support with pride.
- Lightweight, breathable fabric (4.2 oz/yd² or 142 g/m²) for versatile, year-round comfort
- Stylish V-neckline and tailored retail fit
- Tear-away label for added comfort
- Made with 100% cotton (heather colors: 52% cotton, 48% polyester; Athletic Heather: 90% cotton, 10% polyester)
- Bella+Canvas Platinum WRAP certified for ethical manufacturing practices
Share


Recent News
View all-
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
-
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
-
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...